Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Short-term Investments (2019 - 2022)

TransMedics has reported Short-term Investments over the past 4 years, most recently at $27.7 million for Q2 2022.

  • For Q2 2022, Short-term Investments fell 68.14% year-over-year to $27.7 million; the TTM value through Jun 2022 reached $27.7 million, down 68.14%, while the annual FY2021 figure was $66.9 million, 33.83% down from the prior year.
  • Short-term Investments for Q2 2022 was $27.7 million at TransMedics, down from $54.1 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $111.3 million in Q3 2020 and troughed at $27.7 million in Q2 2022.
  • A 4-year average of $70.4 million and a median of $67.4 million in 2019 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: surged 91.12% in 2021 and later crashed 68.14% in 2022.
  • Year by year, Short-term Investments stood at $60.6 million in 2019, then surged by 66.78% to $101.1 million in 2020, then crashed by 33.83% to $66.9 million in 2021, then tumbled by 58.58% to $27.7 million in 2022.
  • Business Quant data shows Short-term Investments for TMDX at $27.7 million in Q2 2022, $54.1 million in Q1 2022, and $66.9 million in Q4 2021.